Epithalon vs SS-31
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, derived from the pineal extract preparation Epithalamin, whose literature reports telomerase induction, telomere elongation in cultured human cells, circadian gene expression changes and lifespan extension in flies and rodents. SS-31, also called elamipretide and MTP-131, is a synthetic tetrapeptide engineered to bind cardiolipin in the inner mitochondrial membrane; it has been through randomised trials in Barth syndrome, primary mitochondrial myopathy, heart failure and Leber hereditary optic neuropathy, and received FDA accelerated approval for Barth syndrome in September 2025. Both are four residues long and both are sold as anti-ageing peptides, which is why they are compared. Beyond that the resemblance stops. No published study has administered or tested them together, and a single 2025 review of skin rejuvenation strategies is the only located publication that names both, listing each separately among approaches to mitochondrial oxidative stress.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No published experiment has administered or tested Epithalon and SS-31 in the same design, in cell culture, in an animal model or in humans. Searches of PubMed field indexes and Europe PMC returned one record that engages both: a 2025 review of genomic and personalised skin rejuvenation strategies, which lists epitalon among antioxidants tested to alleviate mitochondrial oxidative stress in skin ageing and separately notes that elamipretide, a mitochondria-targeted antioxidant, might improve chronic wound healing. Both appear as citations to earlier work rather than as compared interventions, and the review performed no experiment. Everything else in this comparison is indirect, assembled from two literatures that do not overlap in species, endpoint, funding source or research community. That distance matters more than usual here, because the two peptides are alike only in length: one is defined by a claim about telomeres and the pineal axis, the other by a mapped molecular target in the inner mitochondrial membrane and a regulatory dossier.
The publication that covers both
- 01Review2025
A State-of-the-Art Overview on (Epi)Genomics and Personalized Skin Rejuvenating Strategies.
Tauser RG, et al. · Pharmaceutics · narrative review of genomic and epigenomic mechanisms of skin ageing and of personalised rejuvenating strategies, including antioxidant and mitochondria-directed approaches
The review listed epitalon, described as a synthetic tetrapeptide composed of Ala-Glu-Asp-Gly, among antioxidants tested to alleviate mitochondrial oxidative stress in ageing skin, alongside resveratrol, quercetin, vitamins C and E, curcumin, coenzyme Q10 and melatonin. In an adjacent passage it noted that elamipretide, a mitochondria-targeted antioxidant, might also improve chronic wound healing. Both statements were citations to prior literature; neither peptide was administered and no comparison between them was drawn.
Side by side.
| Epithalon | SS-31 | |
|---|---|---|
| Evidence maturity | Early clinical | Approved drug |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 8 | 11 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic tetrapeptide, Ala-Glu-Asp-Gly, modelled on the pineal gland extract preparation Epithalamin. It is not described in the literature as an endogenous human peptide. | A synthetic aromatic-cationic tetrapeptide designed to accumulate in the inner mitochondrial membrane, developed as a drug candidate rather than derived from a tissue extract. |
| Mechanism as described in the literature | Reported to induce telomerase activity and telomere elongation in cultured human somatic cells, to modulate circadian and pineal gene expression, to decondense chromatin in aged cells and to raise antioxidant enzyme activity in rodents. | Binds cardiolipin in the inner mitochondrial membrane, stabilising cristae architecture and improving electron transport efficiency and ATP synthesis, with reduced mitochondrial reactive oxygen species emission reported as a consequence. |
| Size of the evidence base | Fifteen verified studies in this library, of which eight are in vitro, three are animal in vivo, two are human and two are reviews. No randomised controlled trial appears among them. | Sixteen verified studies, of which eleven are human clinical trials, four are animal in vivo and one is a review. |
| Best-characterised finding | Induction of telomerase activity and telomere elongation in human somatic cells, first reported in 2003 and reproduced independently in cell lines in 2025, where the effect was attributed to telomerase upregulation or alternative lengthening of telomeres. | Sustained functional gains in Barth syndrome across a phase 2/3 randomised trial and its long open-label extension, and rapid improvement of in vivo mitochondrial ATP production in aged rodent muscle and in one randomised single-dose study in older adults. |
| Human data | Two human records, a buccal epithelium study of cellular ageing marker proteins and an open, non-randomised report on pineal and thymic peptide preparations. No registered placebo-controlled randomised trial of the synthetic tetrapeptide has been published in the indexed literature. | Multiple randomised controlled trials, with mixed results. The phase 3 MMPOWER-3 trial in primary mitochondrial myopathy missed its primary endpoints, as did the phase 2 heart failure trial and the Leber hereditary optic neuropathy trial. |
| Regulatory status | No approved formulation in any jurisdiction, and no registered clinical trial of the tetrapeptide reported in the indexed literature. The related pineal extract preparation was used in open studies outside modern trial registration. | Granted FDA accelerated approval on 19 September 2025 as FORZINITY, to improve muscle strength in adult and paediatric Barth syndrome patients above a stated weight, on a muscle-strength surrogate endpoint, with continued approval contingent on confirmatory trials. |
| Safety characterisation | Human pharmacokinetics, dose-response and long-term safety are uncharacterised, including any oncological risk that telomerase induction might carry. | Adverse events have been collected under trial conditions across several indications, but long-term safety data outside the small Barth syndrome cohorts remain limited. |
| Basis of most marketing claims | Extrapolation from telomerase induction in cultured cells and from rodent lifespan work to human ageing, without a randomised human trial of the tetrapeptide. | Extrapolation from a rare-disease approval and from rodent ageing studies to exercise capacity, longevity and body composition in healthy people, none of which has been tested in a controlled trial. |
And what it does not.
The two have never been compared, and the separate records are unequal in a way that a shared four-residue length disguises. SS-31 has a mapped molecular target, randomised controlled trials across four indications, and an accelerated FDA approval in Barth syndrome; it also has a phase 3 failure in primary mitochondrial myopathy and negative phase 2 results in heart failure and optic neuropathy, and no controlled trial in healthy people for exercise capacity, longevity or body composition. Epithalon has a specific and striking mechanistic claim, telomerase induction and telomere elongation, reproduced independently in cell lines as recently as 2025, but its corpus is concentrated in one research group, largely published in Russian-language journals, and contains no registered placebo-controlled trial of the synthetic tetrapeptide. Neither compound has controlled human evidence for slowing ageing, which is the use that prompts the comparison. The one review naming both simply lists each among approaches to mitochondrial oxidative stress in skin.
Common questions.
- Has any experiment tested Epithalon against SS-31?
No. Searches of PubMed and Europe PMC returned no study that administered or tested both, in cell culture, in animals or in humans. The only located publication naming both is a 2025 review of skin rejuvenation strategies, which cites epitalon among antioxidants tested against mitochondrial oxidative stress and, separately, notes elamipretide as a mitochondria-targeted antioxidant that might improve chronic wound healing. The review performed no experiment and made no comparison.
- Are they similar molecules because both are tetrapeptides?
Length is where the similarity ends. Epithalon is Ala-Glu-Asp-Gly, an acidic sequence modelled on a pineal gland extract, and its reported activity is nuclear and transcriptional, centred on telomerase and circadian gene expression. SS-31 is an aromatic-cationic sequence engineered to concentrate in the inner mitochondrial membrane, where it binds cardiolipin and stabilises cristae. Different charge, different compartment, different target, and no published work relating one mechanism to the other.
- Which one has been tested in randomised controlled trials?
Only SS-31. Elamipretide has been studied in randomised trials in Barth syndrome, primary mitochondrial myopathy, heart failure with reduced ejection fraction and Leber hereditary optic neuropathy, with mixed results: the phase 3 MMPOWER-3 trial missed its primary endpoints, as did the phase 2 heart failure and optic neuropathy trials. Epithalon has no registered, placebo-controlled randomised trial of the synthetic tetrapeptide in the indexed literature; its human reports used a pineal extract preparation under open designs.
- Does the FDA approval of elamipretide support longevity use?
It does not. The accelerated approval granted in September 2025 covers Barth syndrome, a rare genetic disorder of mitochondrial cardiolipin metabolism, and rests on an improvement in knee extensor muscle strength in a very small cohort, with continued approval contingent on confirmatory trials. The research entry for the compound records that no controlled trial has tested elamipretide in healthy individuals for exercise capacity, athletic performance, longevity or body composition.
- Why is Epithalon research so concentrated in one group?
The compound emerged from the St Petersburg Institute of Bioregulation and Gerontology, and most of the primary work on it, including the rodent lifespan studies and the pineal and circadian findings, was produced there and published in Russian-language journals such as Uspekhi Gerontologii and Byulleten Eksperimentalnoi Biologii i Meditsiny. Independent replication has begun only recently and remains in vitro, with cell-line telomere work appearing between 2022 and 2025. The concentration limits how far the findings can be generalised.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.